Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.
Morgan Stanley likes financials, energy, real estate, and domestically-focused materials and consumer-goods companies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback